Technical Description
This technology describes a device for quantifying glucose and antigen-antibody interaction in biological fluids using enhanced chemiluminescence (ECL) imaging.
Problems Addressed
- Expensive Detection Systems
- Complex Assay Procedures
- Limited In Vivo Compatibility
- Inefficient Glucose Monitoring
- Insufficient Sensitivity & Selectivity
- Non-Optimized Smartphone Integration
Tech Features
- Enhanced Biological Fluid Analysis
- Efficient Smartphone-Based Detection
- Enhanced Analyte Detection
- Enhanced Glucose Detection
- Smartphone-Based ECL Quantification
Target Audience
- Healthcare Sector
- Medical Device Industry
- Biotechnology & Life Sciences Industries
- Pharmaceutical & Diagnostic Industries
- Academic & Research Institutions
Tech ID: P24-1339 TRL 4 Patent Status: Granted Available For Exclusive and Non-exclusive License
